Phenotyping for thiopurine therapy in clinical practice

Journal of Pharmacy Practice and Research

Volumn 38, Issue 3, 2008, Pages 188-190

  Dooley, Michael J ^a,b   Dixon, Barbara ^b   Poole, Susan G ^a   Chiang, Cherie ^c   Whitlock, Alison ^b   Schneider, Hans ^a  

^a MONASH UNIVERSITY   (Australia)

^b The Alfred   (Australia)

^c Alfred Pathology Service   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL PRACTICE; CONTROLLED STUDY; ENZYME ACTIVITY; GRAFT RECIPIENT; HEART LUNG TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PHARMACOGENOMICS; PHENOTYPE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

EID: 55449129197     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2008.tb00835.x     Document Type: Article

References (31)

1. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 2006; 6: 16-21.
2. Winter J, Walker A, Shapiro D, Gaffney D, Spooner R, Mills P. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593-9.
3. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-57.
4. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pbarmacol 1992; 43: 329-39.
5. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, et al. Preponderance of thiopurine S-methylltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301.
6. Andersen JB, Szumlanski C, Weinshilboum R, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatrica 1998; 87: 108-11.
7. Relling M, Pui C, Cheng C, Evans W. Thiopurine methyltransferase in acute lymphoblastic leukaemia. Blood 2006; 107: 843-4.
8. Kaskas BA, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepter F, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut 2003; 52: 140-2.
9. Meggitt S, Gray J, Reynolds N. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double blind, randomised controlled trial. Lancet 2006; 367: 839-46.
10. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005; 15: 365-9.
11. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521-90.
12. Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32: 187-95.
13. Rheumatology Expert Group. Therapeutic Guidelines: Rheumatology. Version 1. Melbourne: Therapeutic Guidelines Limited; 2006.
14. Neurology Expert Group. Therapeutic Guidelines: Neurology. Version 3. Melbourne: Therapeutic Guidelines Limited; 2007.
15. Dermatology Expert Group. Therapeutic Guidelines: Dermatology. Version 2. Melbourne: Therapeutic Guidelines Limited; 2004.
16. Gastrointestinal Expert Group. Therapeutic Guidelines: Gastrointestinal. Version 4. Melbourne: Therapeutic Guidelines Limited; 2006.
17. MIMS Australia. MIMS Online. Donohoo E, editor. St Leonards: MIMS Australia & CMPMedica Australia Pty Ltd; 2008.
18. Shai J. Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ 2004; 328: 1482-6.
19. Koo S, Lee E. Pharmacogenetics approach to therapeutics. Clin Exp Pharmacol Physiol 2006; 33: 525-32.
20. Corkindale DR, Ward H, McKinnon R. The low adoption of pharmacogenetic testing in Australia-an exploratory study of the reasons. Personalised Med 2007; 4: 191-9.
21. De Boer NK, Mulder CJ, van Bodegraven AA. Impracticalities of thiopurine S-methyltransferase determination in daily inflammatory bowel disease practice. Aliment Pharmacol Ther 2006; 23: 1278-9.
22. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008; 8: 4-15.
23. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
24. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-67.
25. Payne K, Newman W, Fargher E, Tricker K, Bruce I, Ollier W. TPMT testing in rheumatology: any better than routine monitoring? Rheumatology 2007; 46: 727-9.
26. Marra C, Esdaile J, Aslam HA. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507-12.
27. Sanderson J, Azhar A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann Clin Biochem 2004; 41: 294-302.
28. Walley T. Evaluating laboratory diagnostic tests. BMJ 2008; 336: 569-70.
29. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
30. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a metaanalysis. Gastroenterology 2006; 130: 1047-53.
31. Teml A, Schaeffeler E, Herrlinger K, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208.